| 15 0 (0%) | 01-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the development and commercialization of therapeutic solutions for cancer patients. Its primary commercial product is FOTIVDA (tivozanib), an oral, once-daily vascular endothelial growth factor receptor tyrosine kinase inhibitor approved for the treatment of renal cell carcinoma (RCC). Tivozanib is also under investigation for other conditions, including hepatocellular carcinoma (HCC), immunologically cold tumors, and cholangiocarcinoma (CCA). The company has successfully concluded a Phase II clinical trial evaluating tivozanib in conjunction with Opdivo (nivolumab) for RCC. AVEO's pipeline includes Ficlatuzumab, a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody designed to target hepatocyte growth factor. This candidate is currently in Phase II clinical trials for squamous cell carcinoma of the head and neck, pancreatic cancer, and acute myeloid leukemia. Also in development is AV-203, a potent humanized IgG1 monoclonal antibody that has completed Phase I clinical trials for its efficacy against human ErbB3. Additionally, AV-380, a powerful humanized IgG1 inhibitory monoclonal antibody, is undergoing Phase I clinical trials for the management or prevention of cachexia. At the preclinical stage, AV-353 is being explored for its activity against the Notch 3 pathway. AVEO Pharmaceuticals, Inc. maintains an extensive network of collaborations, partnering with entities such as CANbridge Life Sciences Ltd., EUSA Pharma (UK) Limited, Novartis International Pharmaceutical Ltd., Biodesix, Inc., St. Vincent's Hospital Sydney Limited, Biogen Idec International GmbH, Kyowa Kirin Co., Ltd., and AstraZeneca PLC. Established in 2001, the company initially operated as GenPath Pharmaceuticals, Inc. before adopting its current name, AVEO Pharmaceuticals, Inc., in March 2005. Its corporate headquarters are located in Boston, Massachusetts.
Wed, 22 Jul 2026
A planned study will compare treatments in advanced kidney cancer - Stock Titan
Tue, 30 Jun 2026
AVEO Oncology Names Michael Ferraresso CEO in Planned Leadership Transition - citybiz
Tue, 30 Jun 2026
AVEO Oncology Announces Succession Plan - PR Newswire
Tue, 26 May 2026
Verastem Oncology Appoints Michael P. Bailey to its Board of Directors - Business Wire
Tue, 05 May 2026
AVEO Oncology, an LG Chem company, Announces Two Poster Presentations at ASCO 2026 Annual Meeting - PR Newswire
Wed, 18 Feb 2026
AVEO Oncology, an LG Chem company, Announces Completion of the First Interim Analysis in the Global Phase 3 FIERCE-HN Study - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|